Zurcher Kantonalbank Zurich Cantonalbank Acquires 945 Shares of Hologic, Inc. (NASDAQ:HOLX)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 354,727 shares of the medical equipment provider’s stock after purchasing an additional 945 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Hologic were worth $28,896,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Prentiss Smith & Co. Inc. lifted its position in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after buying an additional 130 shares during the last quarter. Covestor Ltd grew its holdings in shares of Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its holdings in Hologic by 20.3% in the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock valued at $62,000 after purchasing an additional 140 shares during the last quarter. Finally, Empirical Finance LLC boosted its stake in shares of Hologic by 1.8% during the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after acquiring an additional 147 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Performance

NASDAQ:HOLX opened at $79.44 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock has a market capitalization of $18.45 billion, a P/E ratio of 23.86, a PEG ratio of 2.50 and a beta of 0.98. The company has a 50 day moving average price of $80.28 and a 200 day moving average price of $78.42. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $0.89 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HOLX. Evercore ISI upped their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and cut their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. UBS Group increased their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.